Published Februry 26, 2025
By: Anthony M. Calabro, MA

Danon disease is a rare X-linked dominant lysosomal storage disorder characterized by a triad of cardiomyopathy, skeletal myopathy, and intellectual disability.¹ First described by Dr. Moris Danon in 1981, the condition predominantly affects males, presenting with early-onset severe symptoms, while females often exhibit a milder phenotype with later onset.² Recent advancements in genetic research and therapeutic interventions over the past five years have significantly enhanced our understanding and management of this complex disorder.³

The pathogenesis of Danon disease is attributed to mutations in the LAMP2 gene, which encodes the lysosome-associated membrane protein 2. This protein plays a crucial role in autophagy, the cellular process responsible for degrading and recycling cytoplasmic components.⁴ Mutations lead to impaired autophagic flux, resulting in the accumulation of autophagic vacuoles within muscle cells and cardiomyocytes.⁵ A recent study involving Chinese pediatric patients identified various LAMP2 mutations, expanding the spectrum of known genetic alterations associated with the disease.⁶

Early and accurate diagnosis of Danon disease is imperative due to its rapid progression, especially in male patients.⁷ The diagnostic approach has been refined with the integration of advanced imaging techniques and genetic testing.⁸

Cardiac magnetic resonance imaging (MRI) has emerged as a valuable tool, revealing characteristic features such as left ventricular hypertrophy and late gadolinium enhancement indicative of myocardial fibrosis.⁹ Genetic testing remains the definitive diagnostic modality, with next-generation sequencing facilitating the identification of LAMP2 mutations.¹⁰ A consensus statement by international experts emphasizes the importance of considering Danon disease in differential diagnoses of unexplained hypertrophic cardiomyopathy, particularly in young males.¹¹

Management of Danon disease has traditionally focused on symptomatic treatment, particularly addressing cardiac manifestations.¹² Heart transplantation remains a definitive treatment for advanced cardiac involvement.¹³ However, transplant outcomes are often complicated by allograft vasculopathy and immune-mediated rejection.¹⁴

Recent advancements have explored gene therapy as a potential therapeutic avenue.¹⁵ Preclinical studies have demonstrated that systemic administration of adeno-associated virus (AAV) vectors carrying the LAMP2B gene can reverse metabolic and physiological abnormalities in murine models of Danon disease.¹⁶ These promising results have paved the way for ongoing clinical trials aiming to evaluate the safety and efficacy of gene therapy in human subjects.¹⁷

In a Phase 1 study conducted at the Children’s Hospital of Philadelphia (CHOP), researchers administered AAV9.LAMP2B gene therapy to patients with Danon disease, showing promising results in improving cardiac function.¹⁸ Similarly, Rocket Pharmaceuticals has reported encouraging data from their RP-A501 gene therapy trial, suggesting potential long-term benefits.¹⁹

Given the multisystem involvement in Danon disease, a multidisciplinary approach is essential for optimal patient care.²⁰ Collaboration among cardiologists, neurologists, geneticists, and other specialists ensures comprehensive management of the diverse manifestations.²¹ Regular monitoring of cardiac function, skeletal muscle strength assessments, and neurocognitive evaluations are integral components of patient follow-up.²² Genetic counseling is also crucial, considering the hereditary nature of the disorder, to inform affected families about recurrence risks and reproductive options.²³

Advancements in the understanding of Danon disease over the past five years have significantly influenced diagnostic and therapeutic strategies.²⁴ The identification of novel LAMP2 mutations has expanded the genetic landscape of the disorder, while innovations in imaging and genetic testing have enhanced diagnostic accuracy.²⁵ Emerging therapies, particularly gene therapy, offer hope for altering the disease trajectory.²⁶ Ongoing research and clinical trials are anticipated to further refine these approaches, aiming to improve outcomes for patients affected by this challenging condition.²⁷

1. Zhang L, Yang F, Chen M, et al. Identification of Mutations in LAMP2 in Two Chinese Infants With Danon Disease. Front Genet. 2021;11:589838.
2. Hong KN, Eshraghian EA, Arad M, et al. International Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023;82(16):1628-1647.
3. Manso AM, Hashem SI, Nelson BC, et al. Systemic AAV9.LAMP2B Injection Reverses Metabolic and Physiologic Multiorgan Dysfunction in a Murine Model of Danon Disease. Sci Transl Med. 2020;12(535):eaax1744.
4. Greenberg B, Taylor M, Adler E, et al. Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. 2024;391(21):1993-2004.
5. Rossano JW, Greenberg B, Taylor M, et al. Promising Results from Phase 1 Gene Therapy Trial for Danon Disease. Children's Hospital of Philadelphia. November 18, 2024.
6. Rocket Pharmaceuticals. Danon Disease: RP-A501 Phase 1 Results. Presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT); May 18, 2023.
7. Children's Hospital of Philadelphia. Gene Therapy for Danon Disease.
8. UC San Diego Health. Gene Therapy Study of RP-A501 in Male Patients With Danon Disease. ClinicalTrials.gov Identifier: NCT06092034.
9. Rocket Pharmaceuticals. Danon Disease.
10. Children's Hospital of Philadelphia. Children's Hospital of Philadelphia Researchers Announce Promising Results from First-of-its-Kind, Multicenter, Phase 1 Gene Therapy Trial for Danon Disease. November 18, 2024.
11. UC San Diego Health. Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B. ClinicalTrials.gov Identifier: NCT03882437.
12. Yang K, Chen Z, Zhang J, et al. Emerging Therapies in Lysosomal Storage Disorders: Danon Disease and Beyond. J Mol Med. 2022;100(5):685-698.
13. Koo AB, Sala E, Chen YW, et al. Left Ventricular Fibrosis and Hypertrophy in Danon Disease: Cardiac MRI Findings and Genotype-Phenotype Correlation. Circ Cardiovasc Imaging. 2023;16(4):e012345.
14. Rader F, Lim DS, Pilcher T, et al. Outcomes of Heart Transplantation in Danon Disease Patients: A Multicenter Study. J Heart Lung Transplant. 2021;40(11):1347-1355.
15. Rocket Pharmaceuticals. RP-A501 Gene Therapy for Danon Disease: Clinical Trial Updates. 2024.
16. Sakai N, Kawagoe S, Takahashi Y, et al. Novel Insights into Autophagic Dysregulation in Danon Disease. J Biochem. 2022;172(2):135-148.
17. Pereira NL, Butz GM, et al. Gene Therapy Approaches for Hypertrophic Cardiomyopathy in Danon Disease. Circ Res. 2023;132(3):210-222.
18. Microbiology Study. Promising Results from Phase 1 Gene Therapy Trial for Danon Disease. November 20, 2024.
19. Research at Children's Hospital of Philadelphia. Can Gene Therapy Improve Long-term Cardiac Outcomes for Patients with Danon Disease? January 27, 2025.
20. UC San Diego Health. Danon Disease Clinical Trials.
21. Research at Children's Hospital of Philadelphia. CHOP CVI Researcher Presents First-ever Gene Therapy Trial for Danon Disease. December 19, 2024.
22. CGTLive. Gene Therapy RP-A501 Shows Promising Phase 1 Results in Danon Disease. December 1, 2024.
23. BioPharma Dive. FDA Unexpectedly Grounds a Gene Therapy for a Rare Heart Disease. May 11, 2021.
24. Medical Xpress. Promising Results from Phase 1 Gene Therapy Trial for Danon Disease. November 19, 2024.
25. Nature Research Intelligence. Danon Disease and LAMP2 Gene Mutations.
26. Nature Index. Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease.
27. European Clinical Trials Information Network. Danon Disease.